- Home
- ISPR vs SCPH Comparison
ISPR vs SCPH Comparison
Compare ISPR & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- SCPH
- Stock Information
- Founded
- ISPR 2019
- SCPH 2013
- Country
- ISPR United States
- SCPH United States
- Employees
- ISPR N/A
- SCPH N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- SCPH Health Care
- Exchange
- ISPR Nasdaq
- SCPH Nasdaq
- Market Cap
- ISPR 152.0M
- SCPH 173.6M
- IPO Year
- ISPR 2023
- SCPH 2017
- Fundamental
- Price
- ISPR $2.47
- SCPH $3.84
- Analyst Decision
- ISPR Strong Buy
- SCPH Strong Buy
- Analyst Count
- ISPR 2
- SCPH 3
- Target Price
- ISPR $10.00
- SCPH $14.00
- AVG Volume (30 Days)
- ISPR 42.5K
- SCPH 289.6K
- Earning Date
- ISPR 05-12-2025
- SCPH 08-13-2025
- Dividend Yield
- ISPR N/A
- SCPH N/A
- EPS Growth
- ISPR N/A
- SCPH N/A
- EPS
- ISPR N/A
- SCPH N/A
- Revenue
- ISPR $144,700,345.00
- SCPH $41,982,000.00
- Revenue This Year
- ISPR N/A
- SCPH $108.95
- Revenue Next Year
- ISPR $35.39
- SCPH $73.83
- P/E Ratio
- ISPR N/A
- SCPH N/A
- Revenue Growth
- ISPR N/A
- SCPH 138.10
- 52 Week Low
- ISPR $2.36
- SCPH $1.94
- 52 Week High
- ISPR $8.13
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- ISPR 41.12
- SCPH 56.83
- Support Level
- ISPR $2.36
- SCPH $3.86
- Resistance Level
- ISPR $2.62
- SCPH $4.17
- Average True Range (ATR)
- ISPR 0.17
- SCPH 0.23
- MACD
- ISPR 0.00
- SCPH -0.06
- Stochastic Oscillator
- ISPR 22.45
- SCPH 33.33
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.